Known targets — ChEMBL curated mechanism
SLC6A2SLC6A3SSTR1SSTR2SSTR3SSTR5
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 9/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 6/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GGT1 | P19440 | 4/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 4/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL9292740 | 1.00 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL1259586 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL7703371 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL1301891 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL7706144 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL9293073 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL1301554 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL7700995 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL1301523 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 | |
| Aspartic Acid SCHEMBL1302396 | 0.95 | GRIK1 (0.50) | GRIK1GRIK2GRM1GRM2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114373870-A | Method for improving electron transmission efficiency of tin dioxide-halogenated lead perovskite interface | 中国科学院金属研究所 | 2022-04-19 | — | — | CN | claimed |
| EP-1521590-A1 | NOVEL MEDICAMENT COMBINATIONS BASED ON MAGNESIUM SALTS AND FIBRINOLYTICS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-04-13 | — | — | EP | claimed |
| US-20040087513-A1 | New drug combinations based on sodium channel blockers and magnesium salts | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | claimed |
| US-20040057947-A1 | Drug combinations based on magnesium salts and fibrinolytics | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-03-25 | — | — | US | claimed |
| WO-2004004754-A1 | NOVEL MEDICAMENT COMBINATIONS BASED ON MAGNESIUM SALTS AND FIBRINOLYTICS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-6355771-B1 | MODIFIED BY MERCAPTOALKYLAMINE; CORROSION RESISTANCE, ANTISCALING AGENTS | NIPPON SHOKUBAI CO., LTD. (JP) | 2002-03-12 | — | — | US | claimed |
| EP-0820771-A2 | Pharmaceutical compositions for the treatment of neuropathies containing a lipid-soluble thiamine and a magnesium compound | WÖRWAG PHARMA GmbH (DE) | 1998-01-28 | — | — | EP | claimed |
| EP-0530220-B1 | PHARMACEUTICAL COMPOSITION | S & V ENGINEERING KFT (HU) | 1997-09-03 | — | — | EP | claimed |
| CN-114373870-B | Method for improving electron transmission efficiency of tin dioxide-lead halide perovskite interface | 中国科学院金属研究所 | 2025-02-25 | — | — | CN | disclosed |
| CN-112618466-A | Whitening and moisturizing emulsion and preparation method thereof | 广州小兔科技有限公司 | 2021-04-09 | — | — | CN | disclosed |
| EP-3202408-A2 | POLYSACCHARIDE FOR USE IN PREVENTING METASTASIS FORMATION AND/OR RELAPSE | Fresenius Kabi Deutschland GmbH (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3027196-B1 | POLYSACCHARIDE FOR USE IN PREVENTING METASTASIS FORMATION AND/OR RELAPSE | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2017-03-15 | — | — | EP | disclosed |
| US-20160175340-A1 | POLYSACCHARIDE FOR USE IN PREVENTING METASTASIS FORMATION AND/OR RELAPSE | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3027196-A1 | POLYSACCHARIDE FOR USE IN PREVENTING METASTASIS FORMATION AND/OR RELAPSE | Fresenius Kabi Deutschland GmbH (DE) | 2016-06-08 | — | — | EP | disclosed |
| EP-0980883-A1 | Modified polyaspartic acid, method for production thereof and use therefor | Nippon Shokubai Co., Ltd. (JP) | 2000-02-23 | — | — | EP | disclosed |
| EP-0820771-A2 | Pharmaceutical compositions for the treatment of neuropathies containing a lipid-soluble thiamine and a magnesium compound | WÖRWAG PHARMA GmbH (DE) | 1998-01-28 | — | — | EP | disclosed |
| EP-0530220-B1 | PHARMACEUTICAL COMPOSITION | S & V ENGINEERING KFT (HU) | 1997-09-03 | — | — | EP | disclosed |
| US-5348749-A | Adminstering mixture of zinc, magnesium, and phosphorus compounds; side effect reduction | S+V ENGINEERING KFT. (HU) | 1994-09-20 | — | — | US | disclosed |
| EP-0530220-A1 | PHARMACEUTICAL COMPOSITION. | EGAL VEGYIPARI KOEZOES VALLALA (HU) | 1993-03-10 | — | — | EP | disclosed |
| WO-1991016909-A1 | PHARMACEUTICAL COMPOSITION | S+V ENGINEERING KFT, HUNGARY (HU) | 1991-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087513-A1 | New drug combinations based on sodium channel blockers and magnesium salts | CACNA1B, CACNA1C, CACNA1D | GRIK1 347/4885GRIK2 394/4885GRM1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.